Human testicular (non)seminomatous germ cell tumours: the clinical implications of recent pathobiological insights - PubMed

Affiliations

• PMID: 19253916
• DOI: 10.1002/path.2522

Review

Human testicular (non)seminomatous germ cell tumours: the clinical implications of recent pathobiological insights

Leendert H J Looijenga. J Pathol. 2009 Jun.

Abstract

Human germ cell tumours (GCTs) comprise several types of neoplasias with different pathogeneses and clinical behaviours. A classification into five subtypes has been proposed. Here, the so-called type II testicular GCTs (TGCTs), ie the seminomas and non-seminomas, will be reviewed with emphasis on pathogenesis and clinical implications. Various risk factors have been identified that define subpopulations of men who are amenable to early diagnosis. TGCTs are omnipotent, able to generate all differentiation lineages, both embryonic and extra-embryonic, as well as the germ cell lineage itself. The precursor lesion, composed of primordial germ cells/gonocytes, is referred to as carcinoma in situ of the testis (CIS) and gonadoblastoma of the dysgenetic gonad. These pre-malignant cells retain embryonic characteristics, which probably explains the unique responsiveness of the derived tumours to DNA-damaging agents. Development of CIS and gonadoblastoma is crucially dependent on the micro-environment created by Sertoli cells in the testis, and granulosa cells in the dysgenetic gonad. OCT3/4 has high sensitivity and specificity for CIS/gonadoblastoma, seminoma, and embryonal carcinoma, and is useful for the detection of CIS cells in semen, thus a promising tool for non-invasive screening. Overdiagnosis of CIS due to germ cell maturation delay can be avoided using immunohistochemical detection of stem cell factor (SCF). Immunohistochemistry is helpful in making the distinction between seminoma and embryonal carcinoma, especially SOX17 and SOX2. The different non-seminomatous histological elements can be recognized using various markers, such as AFP and hCG, while others need confirmation. The value of micro-satellite instability as well as BRAF mutations in predicting treatment resistance needs validation in prospective trials. The availability of representative cell lines, both for seminoma and for embryonal carcinoma, allows mechanistic studies into the initiation and progression of this disease.

Similar articles

• Stem cell factor as a novel diagnostic marker for early malignant germ cells.

  Stoop H, Honecker F, van de Geijn GJ, Gillis AJ, Cools MC, de Boer M, Bokemeyer C, Wolffenbuttel KP, Drop SL, de Krijger RR, Dennis N, Summersgill B, McIntyre A, Shipley J, Oosterhuis JW, Looijenga LH. Stoop H, et al. J Pathol. 2008 Sep;216(1):43-54. doi: 10.1002/path.2378. J Pathol. 2008. PMID: 18566970

• Chromosomes and expression in human testicular germ-cell tumors: insight into their cell of origin and pathogenesis.

  Looijenga LH, Gillis AJ, Stoop HJ, Hersmus R, Oosterhuis JW. Looijenga LH, et al. Ann N Y Acad Sci. 2007 Dec;1120:187-214. doi: 10.1196/annals.1411.000. Epub 2007 Oct 2. Ann N Y Acad Sci. 2007. PMID: 17911410 Review.

• Identification of germ cells at risk for neoplastic transformation in gonadoblastoma: an immunohistochemical study for OCT3/4 and TSPY.

  Kersemaekers AM, Honecker F, Stoop H, Cools M, Molier M, Wolffenbuttel K, Bokemeyer C, Li Y, Lau YF, Oosterhuis JW, Looijenga LH. Kersemaekers AM, et al. Hum Pathol. 2005 May;36(5):512-21. doi: 10.1016/j.humpath.2005.02.016. Hum Pathol. 2005. PMID: 15948118

• FOXL2 and SOX9 as parameters of female and male gonadal differentiation in patients with various forms of disorders of sex development (DSD).

  Hersmus R, Kalfa N, de Leeuw B, Stoop H, Oosterhuis JW, de Krijger R, Wolffenbuttel KP, Drop SL, Veitia RA, Fellous M, Jaubert F, Looijenga LH. Hersmus R, et al. J Pathol. 2008 May;215(1):31-8. doi: 10.1002/path.2335. J Pathol. 2008. PMID: 18348162

Cited by

• The two most common histological subtypes of malignant germ cell tumour are distinguished by global microRNA profiles, associated with differential transcription factor expression.

  Murray MJ, Saini HK, van Dongen S, Palmer RD, Muralidhar B, Pett MR, Piipari M, Thornton CM, Nicholson JC, Enright AJ, Coleman N. Murray MJ, et al. Mol Cancer. 2010 Nov 8;9:290. doi: 10.1186/1476-4598-9-290. Mol Cancer. 2010. PMID: 21059207 Free PMC article.

• Testicular cancer: biology and biomarkers.

  Looijenga LH, Stoop H, Biermann K. Looijenga LH, et al. Virchows Arch. 2014 Mar;464(3):301-13. doi: 10.1007/s00428-013-1522-1. Epub 2014 Feb 1. Virchows Arch. 2014. PMID: 24487784 Review.

• Genome wide DNA methylation profiles provide clues to the origin and pathogenesis of germ cell tumors.

  Rijlaarsdam MA, Tax DM, Gillis AJ, Dorssers LC, Koestler DC, de Ridder J, Looijenga LH. Rijlaarsdam MA, et al. PLoS One. 2015 Apr 10;10(4):e0122146. doi: 10.1371/journal.pone.0122146. eCollection 2015. PLoS One. 2015. PMID: 25859847 Free PMC article.

• Local signalling environments and human male infertility: what we can learn from mouse models.

  Nalam RL, Matzuk MM. Nalam RL, et al. Expert Rev Mol Med. 2010 May 11;12:e15. doi: 10.1017/S1462399410001468. Expert Rev Mol Med. 2010. PMID: 20456819 Free PMC article. Review.

• Foxo1 is required in mouse spermatogonial stem cells for their maintenance and the initiation of spermatogenesis.

  Goertz MJ, Wu Z, Gallardo TD, Hamra FK, Castrillon DH. Goertz MJ, et al. J Clin Invest. 2011 Sep;121(9):3456-66. doi: 10.1172/JCI57984. Epub 2011 Aug 25. J Clin Invest. 2011. PMID: 21865646 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Ovid Technologies, Inc.
  • Wiley

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program